Key Highlights
- Tempus AI has broadened its multi-year partnership with Gilead Sciences (GILD) to enhance oncology research through enterprise deployment of the AI-powered Lens platform.
- Gilead now receives comprehensive access to Tempus’ anonymized multimodal patient datasets spanning various cancer categories.
- Tempus’ Diagnostics division reported 111.5% year-over-year revenue expansion in 2025, alongside a 26% increase in oncology test volume.
- The Data and Applications division generated $100.4M in Q4 2025 revenue, reflecting 25.1% YoY growth, while total remaining contract obligations surpassed $1.1 billion.
- TEM shares have advanced 17.9% over the trailing twelve months, contrasting with a 20% decline across the medical information systems sector.
Tempus AI has formalized an enhanced collaboration with Gilead Sciences, building upon an existing framework that already provided valuable real-world oncology datasets to support Gilead’s pharmaceutical development initiatives.
Today we announced an expanded, multi-year collaboration with @GileadSciences aimed at building and advancing Gilead’s oncology pipeline.
“We are so excited to have entered into a strategic collaboration with Gilead whereby our multimodal data and AI-powered insights will… pic.twitter.com/W2cdJj1fnn
— Tempus (@TempusAI) April 9, 2026
Under the revised terms, Gilead gains organization-wide deployment rights to Tempus’ AI-enabled Lens analytics platform. This arrangement enables comprehensive utilization of de-identified patient information across diverse cancer classifications, complemented by specialized analytical support from Tempus’ expert teams.
The original agreement positioned Gilead to leverage Tempus’ data repository for targeted applications including clinical trial architecture, biomarker identification, therapeutic indication evaluation, and patient outcome measurement. The enhanced partnership significantly amplifies these capabilities.
Patrick Loerch, SVP of Clinical Data Science at Gilead, described the collaboration as embodying their “shared priority of putting patients at the heart of innovation.” Ryan Fukushima, CEO of Tempus Data & Apps, emphasized that the expanded platform access would generate AI-powered intelligence to accelerate Gilead’s research and development activities. The companies did not reveal specific financial arrangements.
Strong Diagnostic Performance Underpins Strategic Growth
This partnership extension arrives alongside exceptional performance metrics from Tempus’ diagnostic operations.
Throughout 2025, Tempus‘ Diagnostics division achieved 111.5% revenue expansion compared to the prior year. Oncology assessment volumes increased 26%, Hereditary testing climbed 29%, while minimal residual disease (MRD) testing reached approximately 4,700 tests during Q4 alone—representing 56% sequential growth.
Company leadership projects oncology segment advancement near 30% for 2026, propelled by accelerating genomic sequencing utilization and broader MRD reimbursement frameworks.
The organization continues refining regulatory pricing mechanisms, particularly through transitioning its xT CDx test from laboratory-developed status to FDA-approved classification. The average transaction price during Q4 2025 reached approximately $1,640, representing a $40 improvement from the preceding quarter.
Data Division Demonstrates Consistent Expansion
Tempus‘ Data and Applications division has emerged as a foundational growth engine within the company’s business model.
Fourth-quarter 2025 revenues for this segment totaled $100.4 million, achieving 25.1% year-over-year advancement. Net Revenue Retention measured 126%, signaling that current clients are increasing their platform investment. The organization concluded 2025 holding over $1.1 billion in total remaining contractual obligations.
Executive guidance points toward approximately $1.59 billion in consolidated 2026 revenues, representing roughly 25% growth.
Tempus continues allocating resources toward developing sophisticated AI foundation models utilizing its proprietary clinical datasets, with strategic intentions to diversify beyond oncology into radiology, cardiology, and neuropsychology applications.
Current market valuation positions the stock at a forward price-to-sales multiple of 5.02x, comparing favorably to the industry median of 5.38x.
Gilead remains actively engaged in corporate development initiatives. The pharmaceutical company has disclosed three acquisition transactions totaling approximately $15 billion, encompassing a $7.8 billion Arcellx acquisition and a $5 billion Tubulis transaction. Equity research analysts at TD Cowen, BMO Capital, and Truist Securities currently assign Buy or Outperform ratings on Gilead with price objectives spanning $155 to $174.
